FDA Single Trial Substantial Evidence: A 2026 Sponsor Guide

Short answer: FDA's June 2026 revised draft guidance makes one adequate and well-controlled trial plus confirmatory evidence the starting point for showing FDA single trial substantial evidence of effectiveness, instead of treating it as the exception. The legal standard has not changed, so the burden moves to how persuasive your one trial is and how strong your confirmatory evidence is. Comments are due September 22, 2026, under docket FDA-2019-D-4964.

What did FDA actually publish in June 2026?

On June 22, 2026, HHS launched Operation TrialBlazer, a department-wide initiative to speed up clinical research in the United States. FDA's contribution included a revised draft guidance, "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products" (Revision 1), issued by CDER, CBER and the Oncology Center of Excellence. The notice of availability appeared in the Federal Register on June 24, 2026.

The draft revises FDA's December 2019 draft and, once final, will replace the 1998 guidance "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products." It swaps the 2019 "quality and quantity" framing for a "strength of evidence" framework that weighs trial design, conduct, analysis, results, confirmatory evidence and the wider development program.

Two caveats matter. First, this is a nonbinding draft. Second, FDA's own summary says developers "may be able to rely on" one rigorous pivotal trial plus confirmatory evidence. Some law firms read the draft as a new default; others note it lists the single-trial route first without formally changing the default. Plan on the flexibility, but do not assume it.

How does this connect to the "one pivotal trial" announcement and the Plausible Mechanism Framework?

In February 2026, Martin Makary and Vinay Prasad published "One Pivotal Trial, the New Default Option for FDA Approval" in the New England Journal of Medicine. That article stated the policy but came without guidance. The June draft is the written framework behind it.

Also in February 2026 (issue date February 25), CBER and CDER released a draft guidance on the Plausible Mechanism Framework for individualized therapies that target specific genetic conditions with a known biological cause. It is not a new pathway and does not lower the substantial evidence standard. It applies where the molecular or cellular abnormality is well characterized, the product targets that abnormality or its proximal pathway, and natural history is well understood. Confirmatory evidence can include mechanistic, pharmacodynamic and target engagement data, and a well-characterized natural history can support an externally controlled study.

What counts as confirmatory evidence under the draft?

The draft names several sources. The table summarizes them and what each demands of your program.

The core rule: with no second trial to substantiate results, FDA generally expects either a highly persuasive trial or strong confirmatory evidence. FDA will also weigh conflicting evidence, not only supportive data.

What does the FDA single trial substantial evidence shift mean for European sponsors?

For European biotechs, the biggest opportunity is that well-generated EU data can now carry more weight as confirmatory evidence. A European natural history registry, an EU-run Phase 2 with a clear dose response, or mechanistic data from an academic partner can all strengthen a single US-facing pivotal trial.

The draft also sets limits you need to design around:

EMA expectations have not changed with this draft. If you plan EU and US filings off the same pivotal trial, design for the stricter of the two and document how the US evidence package is built.

When do two trials still make sense?

The draft keeps a clear role for a second trial. Consider two (or one trial with design changes) when:

FDA also notes that two nonidentical trials can be more persuasive than two identical ones, because shared design flaws are less likely to affect both. A highly persuasive trial, such as one showing a substantial mortality reduction, may make a second trial impractical or unethical.

How should you plan and comment before September 22?

FDA wants sponsors to raise their substantial evidence approach early, ideally at the pre-IND meeting and no later than the end-of-phase 2 meeting. See our pre-IND meeting preparation guide and our overview of IND-enabling studies.

• Map every existing data source (EU trials, registries, nonclinical, class data) against the confirmatory evidence types above
• Decide whether your pivotal trial can be highly persuasive on its own or needs strong external support
• Set a US enrollment target for any multiregional pivotal trial
• Prespecify success criteria (and priors, if Bayesian) before the trial starts
• Put the single-trial question on the agenda for your pre-IND or end-of-phase 2 meeting
• Check whether your EU and US evidence plans conflict
• Submit comments at regulations.gov under docket FDA-2019-D-4964 by September 22, 2026

Comments are public, so keep confidential details out of electronic submissions. FDA accepts confidential material only in a paper submission with a redacted copy. Useful comments are specific: ask FDA to define "highly persuasive," clarify how much US enrollment is enough, or confirm how ex-US natural history data will be judged.

Show PXM what you are building

PXM's Operate practice embeds senior operators as fractional heads of regulatory, clinical and CMC, including former FDA reviewers through PXM partners. We build the evidence strategy, prepare the FDA meeting package and draft your docket comments. Explore our FDA pathways work and FDA regulatory affairs service, or contact PXM to review your program before September 22.

Sources